IRAK1 and ovarian serous adenocarcinoma: In mining the Firehose Legacy serous ovarian adenocarcinoma dataset, we also identified that IRAK1 CNA was mutually exclusive from patients with BRCA and DNA damage-related repair gene mutations, defining a possible subset of EOC patients (~25%) that may respond to TIR targeted therapies.